ライフサイエンスコーパス: fecal microbiota

1 r humanized (ex-GF mice colonized with human fecal microbiota).

2 protocol for 16S ribosomal RNA sequencing of fecal microbiota.

3 ffects of co-habitation on skin than oral or fecal microbiota.

4 itivity to colitis and skewed composition of fecal microbiota.

5 ative PCR to monitor and quantify changes in fecal microbiota.

6 ing clinical challenge mostly originating in fecal microbiota.

7 agents that relatively spare the indigenous fecal microbiota.

8 gi, with mixed effects on rumen bacteria and fecal microbiota.

9 ice with colitis, via TLR4, and alters their fecal microbiota.

10 ficant alterations in the composition of the fecal microbiota.

11 is associated with differences in the human fecal microbiota.

12 es and in fecal preparations of mixed murine fecal microbiota.

13 an expansion of the genus Allobaculum in the fecal microbiota.

14 Fecal microbiota 16S rRNA genes, immune cell distributio

15 ced overlap with the deeply sequenced twins' fecal microbiota (18.3 +/- 0.3%, 15.3 +/- 0.3%).

16 th MaR, but not GaM, significantly decreased fecal microbiota abundance and diversity, and expanded t

17 assic approaches, we found no differences in fecal microbiota abundance or composition between patien

18 s and pectinase modulated the composition of fecal microbiota after in vitro fermentation, increasing

19 Fecal microbiota amplicon sequencing from matched indivi

20 Fecal microbiota analyses were performed on patients' st

21 Fecal microbiota analysis of 3 successful FT recipients

22 Fecal microbiota analysis showed reduced bacterial richn

23 Fecal microbiota analysis was performed using 16S riboso

24 levels of tryptophan and composition of the fecal microbiota, analyzed by 16S ribosomal DNA amplicon

25 Here, we explore links between the fecal microbiota and abdominal adiposity using body comp

26 amily member 3 alpha gene (REG3A) alters the fecal microbiota and affects development of colitis in m

27 association between low diversity childhood fecal microbiota and increased diabetes risk.

28 The aim is to investigate fecal microbiota and metabolites at different ages in in

29 n child health and might modulate changes in fecal microbiota and metabolites.

30 We characterized changes in the fecal microbiota and metabolome to identify the mechanis

31 ctors, potentially through modulation of the fecal microbiota and metabolome.

32 We simultaneously measured the fecal microbiota and multiple environmental and host-rel

33 te temporal changes in the concentrations of fecal microbiota and short-chain fatty acids (SCFAs) in

34 dietary protein increased the density of the fecal microbiota and the severity of colitis in SPF mice

35 to 12 mo alters the 16S configuration of the fecal microbiota as read out by amplicon sequence varian

36 Diversity of fecal microbiota, assessed by Shannon index, did not dif

37 We carried out 16S-based profiling of fecal microbiota, assessed the expression of bile acid m

38 The composition of the fecal microbiota associated with serum levels of tryptop

39 crolimus, and mycophenolate mofetil modified fecal microbiota at the family level in each experimenta

40 Fecal microbiota B-diversity segregated patients accordi

41 crobial responses were tested using in vitro fecal microbiota batch fermentations of five donors.

42 n was associated with the composition of the fecal microbiota, but not with constipation or colonic t

43 Metagenomic phylogenetic analysis of fecal microbiota by deep sequencing revealed considerabl

44 We profiled the fecal microbiota by pyrosequencing the gene encoding 16S

45 iltrates from donor stool (FFT), rather than fecal microbiota, can be sufficient to restore normal st

46 results in reduced IL-18 levels and altered fecal microbiota characterized by expanded representatio

47 Prednisolone disrupted fecal microbiota community structure, decreased Bacteroi

48 oos and hosted a strikingly low diversity of fecal microbiota compared to individuals born in natural

49 We did not find significant differences in fecal microbiota composition among patients with differe

50 Fecal microbiota composition analysis was performed in a

51 In the subcohort of 42 children with fecal microbiota composition analysis, the children with

52 g 16S ribosomal gene sequencing, we assessed fecal microbiota composition and diversity, as measured

53 Fecal microbiota composition and inferred function, feca

54 Differences in fecal microbiota composition between groups were analyze

55 rked differences in the small intestinal and fecal microbiota composition between mice housed on clea

56 Analysis of fecal microbiota composition by 16S ribosomal RNA gene s

57 One year after surgery, the fecal microbiota composition differed between CD patient

58 The role of the fecal microbiota composition for the postoperative disea

59 lock component, abolished rhythmicity in the fecal microbiota composition in both genders.

60 The fecal microbiota composition of CD patients, analyzed by

61 Secondly, the fecal microbiota composition of the African swine fever

62 ed the impact of initial alpha-diversity and fecal microbiota composition on beta-diversity instabili

63 Analysis of fecal microbiota composition showed an increase in bacte

64 e adjusted for confounding factors, we found fecal microbiota composition to be associated with devel

65 s of metabolic disease and inflammation, and fecal microbiota composition were assessed.

66 ces in asthma characteristics, food diaries, fecal microbiota composition, and levels of serum inflam

67 .Fecal and serum menaquinone concentrations, fecal microbiota composition, and plasma and fecal cytok

68 In this study, we investigated if the fecal microbiota composition, determined by a high throu

69 lly, delta-infected GSH exhibited an altered fecal microbiota composition, marked by increased inflam

70 Fecal microbiota composition, measured by 16S rRNA seque

71 ssed nutrient intake, food-related behavior, fecal microbiota composition, microbial fermentation, an

72 eral and adipose tissue insulin sensitivity, fecal microbiota composition, plasma and fecal SCFA, ene

73 , lifetime antibiotic use after weaning, and fecal microbiota composition.

74 ns in energy balance, blood metabolomics and fecal microbiota composition.

75 ndry and metagenomics to show that the human fecal microbiota consists largely of taxa and predicted

76 from healthy donors or were given autologous fecal microbiota (control); each transplant was administ

77 Fecal microbiota did not change significantly across all

78 and B-diversity of the 16S configuration of fecal microbiota did not differ between the 2 groups.

79 ently, here we demonstrate that the phyla of fecal microbiota differ substantially between L1-KO mice

80 Fecal microbiota diversity and richness were highest in

81 In this setting, fecal microbiota, evaluated by 16S rRNA gene amplicon se

82 here has been growing interest in the use of fecal microbiota for the treatment of patients with chro

83 Fecal microbiota for transplantation (FMT) is being stud

84 We transplanted fecal microbiota from adult female twin pairs discordant

85 Finally, we found that transplants of fecal microbiota from age-matched APPPS1-21 male mice in

86 tics and subsequently transplanted them with fecal microbiota from Casp1(-/-) mice based on a cohousi

87 ht to investigate whether transplantation of fecal microbiota from drug-free patients with schizophre

88 aised under standard conditions; exposure of fecal microbiota from L2-IL1B mice fed the HFD to L2-IL1

89 The fecal microbiota from mothers and their babies differed

90 T hosts that were recolonized with dysbiotic fecal microbiota from Nod2-deficient mice.

91 ecal microbiota from the mice which received fecal microbiota from patients with constipation also up

92 In this study, fecal microbiota from patients with constipation and hea

93 The mice which received fecal microbiota from patients with constipation present

94 Fecal microbiota from REG3A-TG mice protect non-TG mice

95 The results revealed that transplantation of fecal microbiota from schizophrenic patients into antibi

96 Moverover, fecal microbiota from the mice which received fecal micr

97 We characterized the fecal microbiota from these two species by pyrosequencin

98 TMOP were transmissible by transplanting the fecal microbiota from TMOP-treated mice, indicating that

99 Transplantation of fecal microbiota from women with PCOS or B. vulgatus-col

100 from different studies of the Western adult fecal microbiota generally clustered by study, and the 1

101 Variation in the human fecal microbiota has previously been associated with bod

102 lonized with the patients' and the controls' fecal microbiota, highlighting 78 differentially enriche

103 015), and gamma-proteobacteria domination of fecal microbiota (HR, 2.64; 95% CI, 1.10-5.65; P = 0.031

104 Assessment of fecal microbiota identifies patients at highest risk for

105 This study compared the structure of the fecal microbiota in 29 mestizo children aged 7-18 years,

106 provide novel insights into the role of the fecal microbiota in cardio-metabolic disease with clear

107 We found that dysbiotic fecal microbiota in FA infants evolved compositionally o

108 circadian rhythmicity and composition of the fecal microbiota in mice.

109 of wheat and ATIs on severity of colitis and fecal microbiota in mice.

110 his study, we determine the structure of the fecal microbiota in mothers and neonates according to ma

111 We compared the colonic mucosal and fecal microbiota in patients with chronic constipation a

112 Anti-TNF therapy shifted the diversity of fecal microbiota in patients with IBD, but not with rheu

113 to determine its effects on symptoms and the fecal microbiota in patients with IBS.

114 Baseline fecal microbiota in patients with MPR were enriched with

115 ubstituting antibiotics, this study assessed fecal microbiota in pigs from different dietary treatmen

116 icrobiota are altered in MS by comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 3

117 one prebiotic formula on the same inoculated fecal microbiota in two frequently used batch systems: p

118 es from the mice transplanted with patients' fecal microbiota increased both kynurenic acid synthesis

119 to colonize GF mice shows a direct effect of fecal microbiota independent of active liver inflammatio

120 In conclusion, the structure of the infant fecal microbiota is affected by the maternal H. pylori s

121 Fecal microbiota is often used as a proxy for understand

122 s support the notion that disruptions to the fecal microbiota may help explain the observed effects o

123 ntries, which correlates with alterations in fecal microbiota (microflora) and widespread use of anti

124 spread use of antibiotics and alterations in fecal microbiota ("microflora").

125 emerging under ciprofloxacin pressure in the fecal microbiota, no proof of selection of quinolone-res

126 Therapeutic transplantation of fecal microbiota normalizes brain lesion-induced dysbios

127 A similar shift in the composition of the fecal microbiota occurred after a few months in TG mice

128 iple antimicrobial resistance genes), in the fecal microbiota of 147 mothers and their children sampl

129 The fecal microbiota of 2-month-old infants was considerably

130 acterize bacterial strain composition in the fecal microbiota of 37 U.S. adults sampled for up to 5 y

131 rtium of bacterial strains cultured from the fecal microbiota of a 6-month-old stunted Malawian infan

132 nce during the first 3 wk of life within the fecal microbiota of an infant born at 28-wk gestation.

133 sequencing, plasma/urine metabolomes and the fecal microbiota of Angus steers grazing non-toxic or E+

134 In a longitudinal study of fecal microbiota of children from 5 weeks through 6 to 1

135 The fecal microbiota of domestic and wild suids was analyzed

136 ly, these data suggest that abundance in the fecal microbiota of facultative anaerobes, such as S. Ty

137 irus-like particles (VLPs) purified from the fecal microbiota of five healthy humans.

138 The fecal microbiota of Fut2(-) mice that lack fucosylated h

139 in (150 mg 4 times daily for 10 days) on the fecal microbiota of healthy humans for a period of 1 yea

140 al 16S ribosomal RNA gene sequences from the fecal microbiota of humans and 59 other mammalian specie

141 Autologous transplantation of fecal microbiota of Ldlr(-/-) mice served as control.

142 The fecal microbiota of mice that express hREG3A had a signi

143 Here we analyzed circadian rhythms in the fecal microbiota of mice using deep sequencing, and foun

144 pyridoxamine did not produce alterations in fecal microbiota of mice.

145 Characterization of the fecal microbiota of patients undergoing allogeneic hemat

146 We profiled the fecal microbiota of patients with CDAD (both initial and

147 reduced Clostridia abundance distinguish the fecal microbiota of pre-IBD patients from IBS patients.

148 lic consequences and specific effects on the fecal microbiota of protein and zinc deficiency were pro

149 The fecal microbiota of the hospitalized subjects had abnorm

150 The fecal microbiota of the whole group of patients with cir

151 The fecal microbiota of vaginally delivered infants (both ne

152 However, the profiles of fecal microbiota only partially replicate those of the m

153 t received 100 capsules containing their own fecal microbiota or placebo until month 14.

154 Although no significant changes in fecal microbiota or SCFAs were observed during enteral f

155 E+ grazing affected the fecal microbiota profile; +THI conditions modulated the

156 Fecal microbiota profiles from overweight (n = 29) and o

157 ne pre-treatment rectal gene expression, and fecal microbiota profiles, in 206 pediatric UC patients

158 The groups had similar fecal microbiota profiles, serum markers of inflammation

159 significantly disturbed composition whereas fecal microbiota recovered a similar composition to cont

160 on deficiency altered the composition of the fecal microbiota, reduced mucosal barrier function, and

161 Reconstitution of GF mice with naive fecal microbiota reinstated morphine analgesic tolerance

162 roach begins by identifying uncultured human fecal microbiota samples that transmit immune phenotypes

163 Sigmoid colonic mucosal and fecal microbiota samples were collected from 25 healthy

164 AN fecal microbiota showed a compositional predominance of

165 Fecal microbiota showed covariation with mucosal adheren

166 Two fecal microbiota signatures (Clostridium and Klebsiella

167 SIRT1 iKO mice also had altered fecal microbiota starting at 4-6 months of age compared

168 gnotobiotic mice colonized with a synthetic fecal microbiota, StrainR2 resolves strain abundances wi

169 NA-based analysis of the T-bet(-/-)Rag2(-/-) fecal microbiota suggest that the structure of the endog

170 We identified specific communities of fecal microbiota that are associated with the bioavailab

171 impact on the viability and diversity of the fecal microbiota that is recovered in the laboratory.

172 systematic compositional differences in the fecal microbiota that occurred with age and between West

173 Fecal microbiota transfer was associated with partial co

174 scuss how probiotics, prebiotics, synbiotic, fecal microbiota transfer, polyphenols, specific diets,

175 cal microbiome and were partially rescued by fecal microbiota transfer.

176 Fecal microbiota transfers from Tie2-Cre Arg1fl/fl mice

177 We applied our strategy to a fecal microbiota transplant (FMT) donor stool using mult

178 We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI usin

179 Fecal Microbiota Transplant (FMT) has shown some success

180 pose of this article is to review the use of fecal microbiota transplant (FMT) in the treatment of pe

181 Fecal microbiota transplant (FMT) is a highly efficaciou

182 Fecal microbiota transplant (FMT) is recommended for Clo

183 Fecal microbiota transplant (FMT) reverses the course of

184 metronidazole, vancomycin, fidaxomicin, and fecal microbiota transplant (FMT).

185 mall intestinal cell shedding, whereas adult fecal microbiota transplant alone had no effect.

186 ulate various microbial communities, such as fecal microbiota transplant and bioreactor systems' opti

187 ehavioral symptoms in children with ASD, and fecal microbiota transplant could transform the dysbioti

188 Although fecal microbiota transplant has been used to prevent rec

189 While fecal microbiota transplant has gained increasing popula

190 Conventional fecal microbiota transplant is an adjuvant treatment for

191 eting of the gut microbiota (ie, by means of fecal microbiota transplant).

192 wel cleanse, a stomach-acid suppressant, and fecal microbiota transplant, and observed significant im

193 orientations of some invertons diverge after fecal microbiota transplant, potentially as a result of

194 zed therapeutic purposes, such as autologous Fecal Microbiota Transplant.

195 cacy and safety of diet-modulated autologous fecal microbiota transplantation (aFMT) for treatment of

196 We intend to review the most recent data on fecal microbiota transplantation (FMT) and critically di

197 rial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction o

198 cal evaluation of the safety and efficacy of fecal microbiota transplantation (FMT) as a potential th

199 In particular, fecal microbiota transplantation (FMT) as a treatment st

200 current Clostridium difficile infection with fecal microbiota transplantation (FMT) at a tertiary ref

201 Fecal microbiota transplantation (FMT) can induce remiss

202 We investigated the safety of weekly oral fecal microbiota transplantation (FMT) capsules from hea

203 Fecal microbiota transplantation (FMT) could be a novel

204 We hypothesized that fecal microbiota transplantation (FMT) could be used to

205 Through human-into-mice fecal microbiota transplantation (FMT) experiments from

206 The role of fecal microbiota transplantation (FMT) for Clostridium d

207 fficile infection (CDI) guidelines recommend fecal microbiota transplantation (FMT) for persons with

208 se recovery is apparent given the success of fecal microbiota transplantation (FMT) for recurrent CDI

209 e CDI, fidaxomicin for first recurrence, and fecal microbiota transplantation (FMT) for subsequent re

210 ral case series have reported the effects of fecal microbiota transplantation (FMT) for ulcerative co

211 tudies suggest that weight may be altered by fecal microbiota transplantation (FMT) from a lean donor

212 Fecal microbiota transplantation (FMT) from cancer patie

213 Fecal microbiota transplantation (FMT) has been demonstr

214 Fecal microbiota transplantation (FMT) has been shown to

215 Fecal microbiota transplantation (FMT) has been shown to

216 High-intensity, aerobically prepared fecal microbiota transplantation (FMT) has demonstrated

217 Our understanding and utilization of fecal microbiota transplantation (FMT) has jump-started

218 cerative colitis (UC) patients responsive to fecal microbiota transplantation (FMT) have reduced phag

219 round: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clos

220 BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is a highly effec

221 Fecal microbiota transplantation (FMT) is a highly effec

222 Fecal microbiota transplantation (FMT) is a highly effec

223 se and replacement of the microbiota through fecal microbiota transplantation (FMT) is a promising ap

224 Fecal microbiota transplantation (FMT) is a promising, b

225 Fecal microbiota transplantation (FMT) is an alternative

226 Fecal microbiota transplantation (FMT) is an emerging th

227 Fecal microbiota transplantation (FMT) is highly effecti

228 Fecal microbiota transplantation (FMT) is highly effecti

229 Fecal microbiota transplantation (FMT) is more effective

230 Fecal microbiota transplantation (FMT) is recommended fo

231 Fecal microbiota transplantation (FMT) is used commonly

232 Fecal microbiota transplantation (FMT) may improve dysbi

233 We tested the effect of fecal microbiota transplantation (FMT) on obesity, and p

234 While fecal microbiota transplantation (FMT) presents an attra

235 difficile infections (rCDI) are treated with fecal microbiota transplantation (FMT) provided by healt

236 PURPOSE OF REVIEW: Fecal microbiota transplantation (FMT) re-establishes a

237 expression is regulated by the microbiota as fecal microbiota transplantation (FMT) rescues antibioti

238 Fecal microbiota transplantation (FMT) targeting gut mic

239 the reported promising results of open-label fecal microbiota transplantation (FMT) therapy in patien

240 We report a case in which fecal microbiota transplantation (FMT) utilized for rela

241 rs of antibiotic-resistant microbes and that fecal microbiota transplantation (FMT) would reduce the

242 Fecal microbiota transplantation (FMT), a safe, effectiv

243 roaches to modifying this ecosystem, such as fecal microbiota transplantation (FMT), are being develo

244 e analyze data from two published studies of fecal microbiota transplantation (FMT), finding that hig

245 difficile infections (rCDI) are treated with fecal microbiota transplantation (FMT), using feces prov

246 of the organism has led to increased use of fecal microbiota transplantation (FMT).

247 d as antibiotics, probiotics, synbiotics, or fecal microbiota transplantation (FMT).

248 n, 15.4% vs vancomycin, 25.3%; P = .005) and fecal microbiota transplantation (response rates of 83%-

249 most current and best methods for performing fecal microbiota transplantation and summarize clinical

250 es, with recent clinical trials highlighting fecal microbiota transplantation as a strategy to enhanc

251 a diverse intestinal microbial population by fecal microbiota transplantation attenuates disease and

252 developed and higher quality data to support fecal microbiota transplantation for treating recurrent

253 udy reported higher than 80% success rate of fecal microbiota transplantation for treatment of recurr

254 ready been applied to the clinic, such as in fecal microbiota transplantation for treatment of recurr

255 el diseases (IBDs), where clinical trials of fecal microbiota transplantation have shown some efficac

256 ive therapies like probiotics, curcumin, and fecal microbiota transplantation in the management of mi

257 Fecal microbiota transplantation is an efficacious and i

258 Fecal microbiota transplantation is another emerging the

259 Fecal microbiota transplantation is associated with symp

260 Fecal microbiota transplantation is increasingly used to

261 Fecal microbiota transplantation led to resolution of re

262 Taken together these results suggest that fecal microbiota transplantation may be a treatment opti

263 Fecal microbiota transplantation may have a substantial

264 robes using nonabsorbable antibiotics and by fecal microbiota transplantation of dysbiotic cecal cont

265 responses by treatment with either a healthy fecal microbiota transplantation or defined commensal ba

266 mother-infant pairs and patients undergoing fecal microbiota transplantation to evaluate the pattern

267 Third, we report our use of fecal microbiota transplantation to face severe Clostrid

268 Intervention: Fecal microbiota transplantation with donor stool (heter

269 such as probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and gene manipulation

270 unities for treatment of other diseases with fecal microbiota transplantation, based on findings from

271 Fecal microbiota transplantation, performed in one patie

272 After fecal microbiota transplantation, the SERT expression in

273 Fecal microbiota transplantation, where healthy donor st

274 iseases and findings from clinical trials of fecal microbiota transplantation.

275 commended laboratory screening practices for fecal microbiota transplantation.

276 nd could be transferred to germ-free mice by fecal microbiota transplantation.

277 ridium difficile infection as effectively as fecal microbiota transplantation.

278 or example, administration of probiotics and fecal microbiota transplantation.

279 ow that p-crAssphage can be acquired through fecal microbiota transplantation.

280 ty and reduced fitness that were restored by fecal microbiota transplantation.

281 We also discuss case reports of fecal microbiota transplantations for different disorder

282 Donor-derived fecal microbiota treatments are efficacious in preventin

283 We observed a global alteration of fecal microbiota upon dietary AhR ligand deprivation.

284 We assessed brain activation patterns, fecal microbiota, urine metabolome profiles, serum marke

285 ygen species (ROS) in bacterial cultures and fecal microbiota using 2',7'-dichlorofluorescein diaceta

286 Fecal microbiota varied with diet; the concentration of

287 The profile of the fecal microbiota was associated with colonic transit and

288 The profile of the fecal microbiota was associated with colonic transit bef

289 Fecal microbiota was characterized before surgery and on

290 enters, the diversity of early pretransplant fecal microbiota was lower in patients than in healthy c

291 representation of these 14 duodenal taxa in fecal microbiota was significantly different from that i

292 Fecal microbiota were analyzed by V3-V4 16S ribosomal RN

293 ological, immunohistological parameters, and fecal microbiota were analyzed.

294 Diversity and composition of fecal microbiota were determined by 16S ribosomal RNA ge

295 fects of interventions and breast-feeding on fecal microbiota were investigated.

296 Changes in the composition of fecal microbiota were not associated with liver fat or m

297 Taxonomic profiles of fecal microbiota were obtained prospectively, and conven

298 after each of the treatments, and changes in fecal microbiota were quantified.

299 w that the abundances of Escherichia coli in fecal microbiota were significantly higher in young chil

300 lthy donors and those who received their own fecal microbiota, which may be due to limited numbers.